Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.01
+0.42 (7.51%)
At close: May 12, 2025, 4:00 PM
6.00
-0.01 (-0.17%)
After-hours: May 12, 2025, 7:58 PM EDT
Altimmune Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Altimmune stock ranges from a low of $12 to a high of $26. The average price target of $21 forecasts a 249.42% increase in the stock price over the next year.
Price Target: $21.00 (+249.42%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 3, 2025.
Analyst Ratings
The average analyst rating for Altimmune stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Apr 3, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $25 | Buy | Reiterates | $25 | +315.97% | Apr 2, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Mar 18, 2025 |
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $25 | Buy | Reiterates | $25 | +315.97% | Mar 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +99.67% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
n/a
from 20.00K
Revenue Next Year
n/a
EPS This Year
-1.48
from -1.34
EPS Next Year
-1.75
from -1.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 135.1M | ||
Avg | n/a | n/a | 39.5M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.30 | -1.30 | -0.65 | ||
Avg | -1.48 | -1.75 | -1.33 | ||
Low | -1.66 | -2.26 | -2.12 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.